Clinical Trials Logo

Filter by:
NCT ID: NCT06283615 Recruiting - Intestinal Failure Clinical Trials

Effect of Vitamin D on Skeletal Muscle Function and Qol in Patients With Chronic Intestinal Failure/Insufficiency

Start date: March 12, 2024
Phase: N/A
Study type: Interventional

Eligible patients were randomized into two groups: Vitamin D group and Control group. Control group: routine treatment only, no additional vitamin D intervention therapy. Vitamin D group: In addition to the conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks. The primary and secondary outcomes will be collected.

NCT ID: NCT06282887 Recruiting - Psycho-Oncology Clinical Trials

Effects of Music Therapy on Psychological States Among Cancer Patients Undergoing MRI Scans and A Relevant Mediator

Start date: November 9, 2021
Phase: N/A
Study type: Interventional

The primary objective of this study is to examine the effects of a music therapy protocol on improving anxiety, symptom distress, and relaxation among cancer patients who are going through MRI scanning. Physiological data, such as pulse rates and respiration rates will be collected. Furthermore, data about scanning efficiency will be collected to assess if scanning efficiency is affected by the protocol implementation. The secondary study objective is to assess whether or not there is a relationship between patient attention to music during the intervention process and the changes in anxiety, symptom distress, and relaxation.

NCT ID: NCT06282835 Recruiting - Clinical trials for Pneumonia, Bacterial

Eravacycline Combination Therapy for MRAB

Start date: January 26, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about the eravacycline combination therapy in multidrug-resistant acinetobacter gaumannii pneumonia. The main question is to evaluate the the effectiveness and safety. Participants will be given Eravacycline and Polymyxin,or other antibiotcs that the Investigator considered suitable. During the clinical trial, participants will be monitored for blood drug concentrations and drug concentrations in the ELF (Epithelial Lining Fluid。Clinical efficacy rate and microbiological clearance rate will be assessed at the same time

NCT ID: NCT06282796 Recruiting - Breast Cancer Clinical Trials

Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

Start date: January 1, 2024
Phase:
Study type: Observational

This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.

NCT ID: NCT06282679 Recruiting - Rosacea Clinical Trials

Clinical Observation of Botulinum Toxin A Treatment in the Treatment of Rosacea

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

the goal of this study is to study the clinical efficacy and safety of botox in the treatment of rosacea.

NCT ID: NCT06282497 Recruiting - Clinical trials for Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy

Xerostomia-optimised IMRT Versus Standard IMRT in NPC

Start date: October 23, 2023
Phase: N/A
Study type: Interventional

This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of xerostomia-optimized intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in NPC patients

NCT ID: NCT06282445 Recruiting - Clinical trials for Colorectal Cancer Metastatic

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer.

NCT ID: NCT06282211 Recruiting - Nausea and Vomiting Clinical Trials

the Efficacy and Safety of Ondansetron Oral Soluble Pellicles

Start date: February 20, 2024
Phase: Phase 3
Study type: Interventional

The name of this prospective study is a multicenter, open-label, randomized controlled clinical study of the efficacy and safety of Ondansetron Oral Soluble Pellicles for the prevention of delayed nausea and vomiting induced by highly emetogenic chemotherapy.

NCT ID: NCT06282120 Recruiting - Clinical trials for Metastatic Biliary Tract Cancer

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this clinical trial is to test in biliary tract cancer patients . The main questions it aims to answer are: - To evaluate the efficacy of irinotecan liposome injection combined with 5-FU/LV± immunotherapy for first-line gemsitabine + immunoprogressive metastatic biliary tract cancer - To evaluate the safety of irinotecan liposome injection combined with 5-FU/LV± immunotherapy for first-line gemsitabine + immunoprogressive metastatic biliary tract cancer This study intends to use liposomal irinotecan combined with 5-FU/LV± immunotherapy for second-line treatment of advanced biliary tract cancer that has progressed after gemsitabine + immunotherapy to evaluate the efficacy and safety of this regimen, with a view to providing better treatment options for second-line patients with advanced biliary tract cancer.

NCT ID: NCT06281886 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, randomized, controlled phase II study evaluating induction immuno-chemotherapy and concurrent chemoradiotherapy with or without apatinib in unresectable, locally advanced esophageal squamous cell carcinoma